Syschem (India)

Which are the latest news on Syschem (India)?

How big is Syschem (India)?

As of 10th June, Syschem (India) Ltd has a market capitalization of 215.00 Cr, with recent Net Sales of 573.77 Cr and a Net Profit of 9.48 Cr.

As of 10th June, Syschem (India) Ltd has a market capitalization of 215.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Syschem (India) reported Net Sales of 573.77 Cr and a Net Profit of 9.48 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 91.29 Cr and Total Assets of 216.87 Cr.

Who are in the management team of Syschem (India)?

The management team of Syschem (India) includes Ranjan Jain (Executive Director & Managing Director), Suninder Veer Singh (Executive Director & Wholetime Director), Arshdeep Kaur (Independent Non-Executive Director), Neena Batra (Non-Executive & Non-Independent Director), and Renu Rawat (Independent Non-Executive Director).

The management team of Syschem (India) includes the following individuals:<BR><BR>1. Ranjan Jain - Executive Director & Managing Director<BR>2. Suninder Veer Singh - Executive Director & Wholetime Director<BR>3. Arshdeep Kaur - Independent Non-Executive Director<BR>4. Neena Batra - Non-Executive & Non-Independent Director<BR>5. Renu Rawat - Independent Non-Executive Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Syschem (India)?

Syschem (India) peers include Everest Organics, BDH Industries, Kerala Ayurveda, Nectar Lifesci., Aarey Drugs, Brooks Lab., Oxygenta Pharma, and Sanjiv.Parant. Syschem has a Good growth rating and a 1-year return of -8.13%, better than Kerala Ayurveda's -64.05% but lower than BDH Industries' 49.43%.

Peers: The peers of Syschem (India) are Everest Organics, BDH Industries, Kerala Ayurveda, Nectar Lifesci., Aarey Drugs, Brooks Lab., Oxygenta Pharma, and Sanjiv.Parant.<BR><BR>Quality Snapshot: Excellent management risk is observed at BDH Industries and Sanjiv.Parant., while Average management risk is found at Everest Organics and Nectar Lifesci., and Below Average management risk is noted at Kerala Ayurveda, Aarey Drugs, Syschem (India), Brooks Lab., and Oxygenta Pharma. Growth is rated as Good for Syschem (India), Below Average for Everest Organics, BDH Industries, Kerala Ayurveda, Nectar Lifesci., Aarey Drugs, Brooks Lab., and Oxygenta Pharma, and Good for Sanjiv.Parant. Capital Structure is Excellent at BDH Industries, Good at Syschem (India) and Sanjiv.Parant., and Below Average at Everest Organics, Kerala Ayurveda, Nectar Lifesci., Aarey Drugs, Brooks Lab., and Oxygenta Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is BDH Industries at 49.43%, while the peer with the lowest is Kerala Ayurveda at -64.05%. Syschem (India) has a 1-year return of -8.13%, which is higher than Kerala Ayurveda but lower than BDH Industries. Additionally, the six-month return is negative for Everest Organics, Kerala Ayurveda, Nectar Lifesci., Brooks Lab., Oxygenta Pharma, and Sanjiv.Parant.

Why is Syschem (India) Ltd falling/rising?

As of 10-Jun, Syschem (India) Ltd's stock price is rising to 43.19, indicating a potential shift in market sentiment after a decline. Despite trading below its moving averages, strong fundamentals and increased promoter stake suggest positive long-term prospects.

As of 10-Jun, Syschem (India) Ltd's stock price is rising, currently at 43.19, with a change of 0.26 (0.61%) upward. This increase follows a trend reversal after four consecutive days of decline, indicating a potential shift in market sentiment. The stock has outperformed its sector by 2.67% today, suggesting that it is gaining traction relative to its peers.<BR><BR>Investor participation has also increased, with a delivery volume of 48.18k on June 9, which is a significant rise of 152.76% compared to the five-day average. This heightened activity may reflect growing interest among investors, contributing to the stock's upward movement.<BR><BR>Despite the recent rise, it is important to note that Syschem (India) is currently trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This indicates that while there is a short-term increase, the stock may still be under pressure in the longer term.<BR><BR>The company's fundamentals also support a positive outlook. It has demonstrated strong financial health with a low Debt to EBITDA ratio of 0.04 times, indicating a strong ability to service its debt. Additionally, the company has shown impressive growth in net sales at an annual rate of 52.98% and a remarkable operating profit growth of 388.02%. The consistent positive results over the last six quarters further bolster investor confidence.<BR><BR>Moreover, the promoters have increased their stake in the company by 4.15% in the previous quarter, now holding 60.86% of the company, which signals strong confidence in the company's future prospects. Overall, these factors contribute to the stock's current rise, despite its recent performance trends.

What does Syschem (India) do?

Syschem (India) Ltd manufactures Active Pharmaceutical Ingredients (API) and intermediates in the pharmaceuticals sector. As of March 2026, it reported net sales of 219 Cr and a net profit of 2 Cr, with a market cap of INR 215 Cr.

Overview:<BR>Syschem (India) Ltd is engaged in the manufacturing of Active Pharmaceutical Ingredients (API) and intermediates within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated on December 31, 1993, and was formerly known as Anil Pesticides Limited until its name change on February 17, 2003. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 219 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 215 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 22.00 <BR>Industry P/E: 42 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.05 <BR>Return on Equity: 9.99% <BR>Price to Book: 2.22 <BR><BR>Contact Details:<BR>Address: Tehsil Kalka, Bargodam Village Panchkula Haryana : 133302 <BR>Phone: 91-172-3077777 <BR>Email: info@syschem.in <BR>Website: http://www.syschem.in

Are Syschem (India) Ltd latest results good or bad?

Syschem (India) Ltd's latest results show strong revenue growth with net sales increasing by 55.02% quarter-on-quarter, but net profit fell by 58.27% due to high tax burdens, raising concerns about profitability sustainability. Investors should remain cautious and monitor future performance closely.

Syschem (India) Ltd's latest results present a mixed picture. On one hand, the company achieved impressive net sales of ₹219.35 crores in Q4 FY26, marking a substantial growth of 55.02% quarter-on-quarter and 84.53% year-on-year. This indicates strong demand for its products and reflects a successful operational turnaround from previous years.<BR><BR>However, the net profit of ₹1.74 crores represents a significant decline of 58.27% from the previous quarter, despite the revenue growth. This decline raises concerns about the company's ability to convert sales into profit, especially given that an extraordinary tax burden accounted for 68.93% of pre-tax profits. The profit after tax (PAT) margin has also compressed from 2.95% to 0.79% quarter-on-quarter, highlighting challenges in maintaining profitability.<BR><BR>Overall, while the revenue growth is commendable and reflects a positive trajectory, the volatility in profit margins and the high tax rate suggest underlying operational pressures that could impact the sustainability of earnings. Investors should be cautious and monitor future performance closely to assess the company's ability to stabilize profits moving forward.

Should I buy, sell or hold Syschem (India) Ltd?

How has been the historical performance of Syschem (India)?

Syschem (India) has shown significant sales growth, increasing from 59.00 Cr in Mar'22 to 331.68 Cr in Mar'25, but profitability has declined, with profit after tax dropping from 4.51 Cr in Mar'23 to 0.46 Cr in Mar'25, and cash flow from operations remains negative. Total assets and liabilities grew in tandem, indicating financial challenges despite overall growth.

Answer:<BR>The historical performance of Syschem (India) shows significant fluctuations in key financial metrics over the years, particularly in net sales, operating profit, and profit after tax.<BR><BR>Breakdown:<BR>Syschem (India) has experienced a notable increase in net sales, rising from 59.00 Cr in Mar'22 to 331.68 Cr in Mar'25, reflecting a strong growth trajectory. Total operating income followed a similar trend, reaching 331.68 Cr in Mar'25, up from 59.00 Cr in Mar'22. However, the company's total expenditure also increased significantly, from 58.44 Cr in Mar'22 to 327.69 Cr in Mar'25, primarily driven by rising raw material costs, which surged from 46.97 Cr in Mar'22 to 310.87 Cr in Mar'25. Operating profit (PBDIT) showed volatility, peaking at 8.90 Cr in Mar'23 but dropping to 4.03 Cr in Mar'25. Profit before tax also fluctuated, with a high of 6.15 Cr in Mar'23 and a decline to 1.01 Cr in Mar'25. Profit after tax mirrored this trend, decreasing from 4.51 Cr in Mar'23 to 0.46 Cr in Mar'25. The company's total assets grew from 55.87 Cr in Mar'22 to 216.87 Cr in Mar'25, while total liabilities increased from 55.87 Cr to 216.87 Cr in the same period. Cash flow from operating activities remained negative, indicating ongoing challenges in generating cash from core operations, although cash flow from financing activities showed improvement, contributing to a net cash inflow of 2.00 Cr in Mar'25. Overall, Syschem (India) has shown growth in sales and assets, but profitability and cash flow remain areas of concern.

Is Syschem (India) overvalued or undervalued?

As of August 6, 2025, Syschem (India) is considered very expensive with a PE ratio of 100.12 and low ROCE and ROE, indicating it is overvalued at its current price of 45.79 despite a recent positive stock performance.

As of 6 August 2025, the valuation grade for Syschem (India) has moved from expensive to very expensive. The company is currently overvalued, with a PE ratio of 100.12, an EV to EBITDA of 34.95, and a PEG ratio of 2.03. In comparison, peers such as Solar Industries and Gujarat Fluoroch are also categorized as very expensive, with PE ratios of 112.38 and 64.46, respectively, highlighting that Syschem's valuation is not an outlier in the industry but remains significantly high.<BR><BR>Despite the recent stock performance showing a 3.93% return over the past week compared to a -1.15% return for the Sensex, the overall valuation metrics indicate that Syschem (India) is not justified at its current price of 45.79. The low ROCE of 1.16% and ROE of 2.18% further emphasize the disconnect between its market price and fundamental performance, reinforcing the conclusion that the stock is overvalued.

Who are the top shareholders of the Syschem (India)?

The top shareholders of Syschem (India) include promoter Virendra Popatlal Shah with 10.43%, and Ashika Global Finance Private Limited as the largest public shareholder at 4.44%. Individual investors hold a combined 33.37%, with no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Syschem (India) include the promoters, with Virendra Popatlal Shah holding the highest individual stake at 10.43%. In terms of public shareholders, Ashika Global Finance Private Limited is the largest, owning 4.44%. Additionally, individual investors collectively hold 33.37% of the company's shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares.

What is the technical trend for Syschem (India)?

As of May 12, 2025, Syschem (India) shows a mildly bearish trend with mixed signals from key indicators, including a mildly bullish weekly MACD and a mildly bearish monthly MACD, suggesting a lack of strong momentum.

As of 12 May 2025, the technical trend for Syschem (India) has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands show a bullish stance on the weekly chart but are mildly bearish on the monthly chart. Moving averages on the daily timeframe are mildly bearish, suggesting short-term weakness. The KST is mildly bullish on the weekly and mildly bearish on the monthly, further contributing to the mixed outlook. Overall, the current technical stance is mildly bearish, with key indicators reflecting a lack of strong momentum in either direction.

When is the next results date for Syschem (India)?

No Upcoming Board Meetings

Has Syschem (India) declared dividend?

No Dividend History Available